Results 31 to 40 of about 12,300 (184)

Epitope mapping of antibodies to alpha-synuclein in LRRK2 mutation carriers, idiopathic Parkinson disease patients and healthy controls.

Frontiers in Aging Neuroscience, 2014
Alpha-synuclein (Snca) plays a major role in Parkinson Disease (PD). Circulating anti-Snca antibodies have been described in PD patients and healthy controls, but they have been poorly characterized.
Beatriz eAlvarez-Castelao, Ana eGorostidi, Javier eRuiz-Martinez, Adolfo eLópez de Munain, Jose G Castaño   +4 more
doaj   +1 more source

A protocol for the study of environmental risk factors and candidate gene–environment interactions in neurodegenerative disorders in Nigeria (SERGEND): A cross-sectional descriptive study

Journal of Clinical Sciences
Introduction: The risk of developing neurodegenerative disorders (NDDs) such as Alzheimer’s disease and related dementias (ADRD) and Parkinson’s disease and atypical parkinsonism (PDAP), has been alluded to arise predominantly from the interplay between ...
Oluwadamilola Omolara Ojo, Osigwe P Agabi, Ismail O Ishola, Olajumoke O Oshinaike, Sani A Abubakar, Kolawole W Wahab, Abiodun H Bello, Rufus O Akinyemi, Uduak Williams, Simon I Ozomma, Oluchi Ekenze, Emmanuel Iwuozo, Yakub W Nyandaiti, Francis I Ojini, Henry Houlden, John Hardy, Njideka Ulunma Okubadejo   +16 more
doaj   +1 more source

Generation of gene-corrected iPSC line from Parkinson's disease patient iPSC line with alpha-SNCA A53T mutation

Stem Cell Research, 2018
Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder. PD can result from a mutation of alpha-synuclein (α-SNCA), such as α-SNCA A53T.
Seo-Young Lee, SangKyun Jeong, Janghwan Kim, Sun-Ku Chung   +3 more
doaj   +1 more source

Genetic Elements at the Alpha-Synuclein Locus

Frontiers in Neuroscience, 2022
Genome-wide association studies have consistently shown that the alpha-synuclein locus is significantly associated with Parkinson’s disease. The mechanism by which this locus modulates the disease pathology and etiology remains largely under-investigated.
Jordan Prahl, Gerhard A. Coetzee
doaj   +1 more source

SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes [PDF]

Human Mutation, 2011
Genomic multiplication of the alpha-synuclein gene (SNCA) locus is one cause of familial Parkinson disease (PD). We performed detailed genomic, SNCA expression level, clinical, neuropsychological and functional imaging analyses of a parkinsonian kindred with a known duplication of the SNCA locus.
Mutez, Eugénie, Lepretre, Frederic, Le Rhun, Emilie, Larvor, Lydie, Duflot, Aurélie, Mouroux, Vincent, Kerckaert, Jean-Pierre, Figeac, Martin, Dujardin, Kathy, Destée, Alain, Chartier-Harlin, Marie-Christine   +10 more
openaire   +2 more sources

Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain

Parkinson's Disease, 2012
Duplications and triplications of the α-synuclein (SNCA) gene increase risk for PD, suggesting increased expression levels of the gene to be associated with increased PD risk.
Alexandra Dumitriu, Carlee Moser, Tiffany C. Hadzi, Sally L. Williamson, Christopher D. Pacheco, Audrey E. Hendricks, Jeanne C. Latourelle, Jemma B. Wilk, Anita L. DeStefano, Richard H. Myers   +9 more
doaj   +1 more source

A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism

Frontiers in Neurology, 2018
Chronic alpha-synuclein (SNCA) overexpression is a relatively homogenous and well-defined cause of parkinsonism and dementia. Parkinson's disease (PD), PD with dementia, dementia with Lewy bodies and multiple system atrophy all manifest in SNCA ...
Adam Book, Ilaria Guella, Tara Candido, Alexis Brice, Nobutaka Hattori, Beomseok Jeon, Matthew J. Farrer, SNCA Multiplication Investigators of the GEoPD Consortium   +7 more
doaj   +1 more source

In vivo silencing of alpha-synuclein using naked siRNA

Molecular Neurodegeneration, 2008
Background Overexpression of α-synuclein (SNCA) in families with multiplication mutations causes parkinsonism and subsequent dementia, characterized by diffuse Lewy Body disease post-mortem.
Charisse Klaus, Toudjarska Ivanka, Kent Caroline, Hinkle Kelly, Ogholikhan Sina, He Zhen, Braithwaite Adam, Lincoln Sarah, Zehr Cynthia, Hope Andrew, Bumcrot David, Melrose Heather, Lewis Jada, Braich Ravi, Pandey Rajendra K, Heckman Michael, Maraganore Demetrius M, Crook Julia, Farrer Matthew J   +18 more
doaj   +1 more source

SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex

Acta Neuropathologica Communications, 2022
Antisense oligonucleotide (ASO) therapy for neurological disease has been successful in clinical settings and its potential has generated hope for Alzheimer’s disease (AD).
Jennifer L. Brown, Damyan W. Hart, Gabriel E. Boyle, Taylor G. Brown, Michael LaCroix, Andrés M. Baraibar, Ross Pelzel, Minwoo Kim, Mathew A. Sherman, Samuel Boes, Michelle Sung, Tracy Cole, Michael K. Lee, Alfonso Araque, Sylvain E. Lesné   +14 more
doaj   +1 more source

LncRNA-UCA1 promotes PD development by upregulating SNCA.

European review for medical and pharmacological sciences, 2018
The study aims to investigate whether Long non-coding RNA (LncRNA)-UCA1 can regulate the progression of Parkinson's disease (PD) by mediating a-synuclein (SNCA) expression.PD mouse model was first constructed by intraperitoneal injection of MPTP. SH-SY5Y cells were treated with MPP+ for inducing in vitro PD model.
Lu, M., Sun, W.-L., Shen, J., Wei, M., Chen, B., Qi, Y.-J., Xu, C.-S.   +6 more
openaire   +2 more sources